key: cord-1022142-lq1n1cvp
authors: Polansky, Hanan; Lori, Gillad
title: Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections
date: 2020-04-10
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.105971
sha: 065276cbc8f0423ba2694473000d36d8afc07da9
doc_id: 1022142
cord_uid: lq1n1cvp

nan

The novel coronavirus (COVID-19) outbreak imposes a significant threat to global health with an estimated R 0 of 2.24-4.08 and fatality rate of 3.4%. Samples collected from COVID-19 patients revealed that the novel virus is a betacoronavirus, closely related to the human Severe Acute Respiratory Syndrome (SARS-CoV) with 79.5% sequence identity 1 oxidative stress, and results in a decreased response of the immune system to viruses, and an increased rate of mutation of RNA viruses. The combination of an increase in viral rate of mutation with a decrease in the immune response, has been linked to increased virulence, as it may give rise to a larger population of quasispecies, of which new, more pathogenic quasispecies may emerge. M. Harthill 11 suggested that this mechanism, which has been observed for other RNA viruses in Se deficient mice models, also occurred in the SARS-CoV outbreak, which emerged in areas of low Se soil in China, such as Wuhan city. Studies showed that Se supplementation to Se deficient patients increased the immune response to viral infections, and decreased the virulence of several viruses, in some cases to the point of complete prevention of the disease 10 .

In summary, in this paper we described the effects of Gene-Eden-VIR/Novirin ingredients on betacoronaviruses, and specifically SARS-CoV. We chose SARS-CoV because of its high level of sequence identity to COVID-19. We showed that Gene-Eden-VIR/Novirin ingredients exert a variety of antiviral effects on betacoronaviruses, and SARS-CoV, including inhibition of cell entry and infection, inhibition of replication, inhibition of the viral proteases, enhancing the antiviral immune response, and reducing virulent quasispecies formation. We regard the evidence presented in this paper as first indication of efficacy. Next, we are planning to collect clinical data on the effect of Gene-Eden-VIR/Novirin on the SARS-CoV-2 virus from users of the treatments. We will use this clinical data to further our understanding of the effects of the treatments on individuals at risk and those infected with the virus.

Competing Interests: Hanan Polansky is the inventor of the Gene-Eden-VIR/Novirin formula. Gillad Lori has no conflict of interest.

Ethical Approval: Not required

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Homology Models of Coronavirus 2019-nCoV 3CLpro Protease

Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus. Drug Design, Development and Theory

Novirin in Oral Herpes

Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris

Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors

Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs against COVID-19

Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection

The Effect of Echinacea purpurea, Astragalus membranaceus and Glycyrrhiza glabra on CD69 Expression and Immune Cell Activation in Humans

Selenoproteins and Viral Infection

Review: Micronutrient Selenium Deficiency Influences Evolution of

Some Viral Infectious Diseases